Capricor Therapeutics Inc [CAPR] stock prices are up 9.53% to $11.15 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The CAPR shares have gain 34.99% over the last week, with a monthly amount glided 4.69%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Capricor Therapeutics Inc [NASDAQ: CAPR] stock has seen the most recent analyst activity on June 26, 2025, when B. Riley Securities initiated its Buy rating and assigned the stock a price target of $21. Previously, Roth Capital started tracking the stock with Buy rating on May 20, 2025, and set its price target to $31. On October 21, 2024, Piper Sandler initiated with a Overweight rating and assigned a price target of $35 on the stock. Oppenheimer started tracking the stock assigning a Outperform rating and suggested a price target of $14 on May 17, 2024. Cantor Fitzgerald initiated its recommendation with a Overweight and recommended $8 as its price target on January 05, 2024. Ladenburg Thalmann started tracking with a Buy rating for this stock on October 26, 2022, and assigned it a price target of $15. In a note dated December 26, 2018, Maxim Group downgraded an Hold rating on this stock.
The stock price of Capricor Therapeutics Inc [CAPR] has been fluctuating between $3.52 and $23.40 over the past year. Currently, Wall Street analysts expect the stock to reach $15.38 within the next 12 months. Capricor Therapeutics Inc [NASDAQ: CAPR] shares were valued at $11.15 at the most recent close of the market. An investor can expect a potential return of 37.94% based on the average CAPR price forecast.
Analyzing the CAPR fundamentals
The Capricor Therapeutics Inc [NASDAQ:CAPR] reported sales of 17.36M for trailing twelve months, representing a drop of -100.00%. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -3.3%, Pretax Profit Margin comes in at -3.17%, and Net Profit Margin reading is -3.17%. To continue investigating profitability, this company’s Return on Assets is posted at -0.36, Equity is -0.62 and Total Capital is -0.44. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 10.23 points at the first support level, and at 9.32 for the second support level. However, for the 1st resistance point, the stock is sitting at 11.82, and for the 2nd resistance point, it is at 12.50.
Ratios To Look Out For
It’s worth pointing out that Capricor Therapeutics Inc [NASDAQ:CAPR]’s Current Ratio is 6.55. Also, the Quick Ratio is 6.55, while the Cash Ratio stands at 1.29. Considering the valuation of this stock, the price to sales ratio is 29.36, the price to book ratio is 3.99.
Transactions by insiders
Recent insider trading involved Nippon Shinyaku Co Ltd, 10% Owner, that happened on Sep 20 ’24 when 2.8 million shares were purchased.
